Table 1 Variables associated with log-transformed IgG titers 1 month post boost dose (+30 v2) (univariate and multivariate linear regression analysis).
From: B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV
Univariate analysis | P | Multivariate analysis | P | |
|---|---|---|---|---|
Mean change (95% CI) | Adjusted mean change (95% CI) | |||
Age, per +10 years | 0.11 (–0.05/0.26) | 0.169 | ||
Male gender | –0.10 (–0.43/0.23) | 0.563 | ||
Type of vaccine (mRNA-1273 vs. BNT162b2) | –0.07 (–0.37/0.22) | 0.623 | ||
BMI, kg/m2 | –0.00 (–0.03/0.02) | 0.836 | ||
IDU | 0.03 (–0.36/0.43) | 0.864 | ||
Years from HIV infection, per +10 years | 0.03 (–0.12/0.17) | 0.731 | ||
CDC stage C | –0.15 (–0.53/0.23) | 0.426 | ||
HBV or HCV coinfection | –0.05 (–0.36/0.25) | 0.736 | ||
Zenith HIV-RNA, per +1 log copies/mL | –0.01 (–0.28/0.27) | 0.946 | ||
CD4 cell count at nadir, per +100 cell/mmc | 0.07 (–0.02/0.16) | 0.124 | ||
Years from first ART, per +10 years | 0.06 (–0.12/0.23) | 0.526 | ||
InSTI + 2NRTI | –0.10 (–0.40/0.20) | 0.503 | ||
Baseline HIV-RNA <50 cp/mL | 0.25 (–0.28/0.79) | 0.347 | ||
Time from last HIV-RNA > 50 copies/mL, per +10 years | –0.02 (–0.47/0.44) | 0.942 | ||
CD4 cell count at baseline, per +100 cell/mmc | 0.04 (–0.01/0.08) | 0.102 | ||
CD4 cell count at baseline ≤350 cell/mmc | –1.08 (–1.41/–0.75) | <0.001 | –1.02 (–1.39/–0.65) | <0.001 |
CD4% ≥ 30% | 0.36 (0.09/0.64) | 0.009 | 0.01 (–0.30/0.32) | 0.947 |
CD4/CD8 ratio ≥1 | 0.33 (0.06/0.60) | 0.019 | 0.11 /–0.19/0.40) | 0.459 |
Comorbidities: | ||||
Diabetes | –0.42 (–0.94/0.11) | 0.120 | ||
Hypertension | 0.21 (–0.14/0.59) | 0.264 | ||
Chronic lung disease | 0.27 (–0.17/0.72) | 0.223 | ||
Previous cancer | 0.05 (–0.40/0.50) | 0.835 | ||
